Boyds has announced a key appointment in support of its continuing growth plans, welcoming Claire Scruton as Senior Manager of CMC Regulatory Affairs.
At Boyds, Claire will provide strategic regulatory CMC advice and operational support across a range of therapeutic areas and development stages for ATMPs, biologics and new chemical entities.
A CMC regulatory affairs professional, Claire has more than 20 years’ experience in the pharmaceutical industry and an extensive background in biological and inhalation product development. A member of the General Pharmaceutical Council, the Royal Pharmaceutical Society and TOPRA, Claire has a successful track record in delivering CMC regulatory strategies and submissions for development and marketed products.
Claire joins Boyds from Mundipharma where she was a Regulatory Affairs Senior Manager in CMC and Compliance, and the lead for a diverse range of development and marketed products including new chemical entities and biologics.
Prior to this, Claire was at Pfizer for 13 years, working in process and formulation development of inhaler products, as well as in biologics formulation development.
Commenting on her appointment, Claire said: “My role at Boyds will provide me with the opportunity to work with internal experts and clients who are carrying out pioneering work in the field of ATMP product development. I’m looking forward to contributing to these exciting projects, and, in turn, supporting the development of novel drug products that will ultimately make a difference to the lives of patients.”
Professor Alan Boyd, Founder and CEO of Boyds, added: “Demand for our regulatory services is growing, and I am delighted to welcome Claire to our Regulatory Affairs team at this exciting time. Claire’s extensive experience and expertise in CMC Regulatory Affairs will complement and enhance our service offering to clients and add great value to their projects.”
Claire will be based at the Cambridge office.
